BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
BioAge Labs, Inc.NASDAQ: BIOA
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 28.0% from a year ago
Other current liabilities stood at $714K at the end of Q1 FY2026, up 28.0% from a year earlier and up 36.0% from the prior quarter. Over 3 fiscal years it compounded at +179.7% a year.
Context
- Other current liabilities amounted to 0.2% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +28.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 525K USD
- Year-over-year change
- +25.9%
- 3-year CAGR
- +179.7%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 525K | +25.9% |
| FY2024 | 2024-12-31 | 417K | -70.0% |
| FY2023 | 2023-12-31 | 1.39M | +5687.5% |
| FY2022 | 2022-12-31 | 24K | — |
Other Current Liabilities vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +28.0% is the 4th highest of 6, against a peer median of +35.6%.
- Other current liabilities amounts to 0.2% of total assets for BIOA, versus a peer median of 3.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$74.64M CAD | +135.2% | -8.3% | 6.7% | |
| Mar 2026 | $23.29M USD | — | +31.3% | 8.7% | |
| Mar 2026 | $18.47M USD | +35.6% | — | 12.4% | |
| Mar 2026 | $14.98M USD | — | -17.0% | 3.8% | |
| Mar 2026 | $8.37M USD | +148.1% | +94.5% | 5.6% | |
| Dec 2025 | $6.05M USD | — | — | 2.6% | |
| Mar 2026 | $3.36M USD | — | — | 3.4% | |
| Mar 2026 | CA$2.39M CAD | -91.4% | -17.6% | 0.4% | |
BIOABioAge Labs, Inc. | Mar 2026 | $714K USD | +28.0% | +179.7% | 0.2% |
| Mar 2026 | $0 USD | -100.0% | +16.2% | 0.0% | |
| Peer median (excluding BIOA) | — | +35.6% | +3.9% | 3.8% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.